Depatuxizumab mafodotin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Depatuxizumab mafodotin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Depatuxizumab mafodotin can convert its Antibody drug conjugate (ADC) profile and EGFR x Tubulin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Depatuxizumab mafodotin (query alias: Depatuxizumab mafodotin) |
|---|---|
| Modality / target | Antibody drug conjugate (ADC); EGFR x Tubulin; EGFR antagonists, Tubulin inhibitors |
| Highest global status | Phase 2 |
| Originator | AbbVie, Inc. |
| Active developers | AbbVie, Inc. |
The MCP disease footprint includes Non-Small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT02573324 | Phase 3 | Completed | 691 | Overall Survival (OS) |
| NCT03419403 | Phase 3 | Terminated | 40 | Percentage of Participants Who Required a Change in Ocular Side Effect (OSE) Management |
| NCT02590263 | Phase 1/2 | Completed | 53 | Percentage of participants with adverse events |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
CTNI-59. TUMOUR VOLUMES PREDICT PROGNOSIS AND RESPONSE TO TREATMENT WITH DEPATUXIZUMAB MAFADOTIN
Phase 2; n=260; evaluation: Positive. Reported fields: OS = 309 days ; OS = 356 days ; OS = 309 days
Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial
Phase 3; n=639; evaluation: Negative. Reported fields: mOS = 18.7 Month ; mOS = 18.9 Month
Safety and Efficacy of Depatuxizumab Mafodotin in Japanese Patients With Malignant Glioma: A Non-randomized, Phase 1/2 Trial.
Phase 1/2; n=53; evaluation: not stated. Reported fields: 6-month PFS = 25.6 % (95%CI, 11.4 - 42.6)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Depatuxizumab mafodotin addresses Non-Small Cell Lung Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Antibody drug conjugate (ADC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 172 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: EGFR x Tubulin records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-07-21 | 27.6亿元！同源康与齐鲁制药达成战略投资与授权协议 | NDA/BLA | US$10.3M upfront; US$304.4M milestones |
| 2026-07-14 | Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy | Approved | US$600.0M upfront; US$900.0M milestones |
| 2026-05-18 | 全面强化肺癌治疗版图！复宏汉霖引进正大丰海/江苏创特三代口服EGFR-TKI | NDA/BLA | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Use of multi-target tyrosine kinase inhibitor in combination with EGFR inhibitor in preparing drug for treating tumor”. The milestone feed surfaced a patent-application signal described as “Use of combination of JAK kinase inhibitor and EGFR inhibitor in preparation of medicament for treating tumor diseases”. The milestone feed surfaced a patent-application signal described as “Use of CDK4/6 inhibitor in combination with EGFR inhibitor in the preparation of medicament for treating tumor diseases”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- CLDN18.2 assay, cutoff, and intratumoral heterogeneity
- Payload-related toxicity and dose intensity
- Crowding from antibodies, bispecifics, CAR-Ts, and competing ADCs
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
